Breaking News Instant updates and real-time market news.

MRK

Merck

$53.36

-1.17 (-2.15%)

07:57
04/09/18
04/09
07:57
04/09/18
07:57

Technical Take: Merck up after Phase 3 KEYNOTE-042 trial met primary endpoint

In pre-market trading the stock was last up over 2.69% to $54.80. At that price next resistance is at $55.25 and then at $55.96. Support is at the $54 area.

  • 09

    Apr

  • 14

    Apr

  • 23

    Apr

  • 24

    Apr

  • 01

    May

  • 08

    May

  • 23

    Oct

MRK Merck
$53.36

-1.17 (-2.15%)

04/06/18
MZHO
04/06/18
NO CHANGE
Target $103
MZHO
Buy
Mizuho says failure of Incyte's epacadostat ups chances of Nektar takeover
Mizuho analyst Difei Yang raised her price target on Nektar Therapeutics (NKTR) to $103 from $89 after Incyte (INCY) announced this morning the failure of epacadostat in combination with Merck's (MRK) Keytruda in a phase 3 study in melanoma patients. Recent clinical data presented by Nektar reinforced her view of NKTR-214 as one of the most impressive combo agent for checkpoint inhibitors, said Yang, who believes that the failure of epacadostat raises the possibility of a takeout by Bristol-Myers (BMY) in the coming months. She maintains a Buy rating on Nektar shares, which are down 8.5% to $92.75 in afternoon trading.
04/09/18
JEFF
04/09/18
DOWNGRADE
Target $4
JEFF
Hold
NewLink Genetics downgraded to Hold with $4 target at Jefferies
Jefferies analyst Biren Amin late Friday downgraded NewLink Genetics (NLNK) to Hold from Buy and cut his price target for the shares to $4 from $17. The stock closed Friday down 43%, or $3.12, to $4.20. The analyst does not see a scenario in which the company's IDO inhibitor can avoid the same fate as Incyte and Merck's epacadostat plus Keytruda failed study.
04/09/18
OPCO
04/09/18
NO CHANGE
Target $65
OPCO
Perform
Incyte price target lowered to $65 from $110 at Oppenheimer
Oppenheimer analyst Jay Olson lowered his price target for Incyte (INCY) to $65 from $110 following the update on the termination of ECHO-301 after epacadostat failed to show a PFS or OS benefit when combined with Merck's (MRK) Keytruda versus Keytruda alone. While the company plans to conduct subgroup analyses of ECHO-301 looking at various biomarkers such as PD-L1 expression and tumor mutational burden which may provide additional insights, the analyst sees no reason at this time to continue development of epacadostat as he considers it highly unlikely to demonstrate efficacy in other tumor types and/or combinations. Olson reiterates a Perform rating on Incyte's shares.
04/09/18
HCWC
04/09/18
NO CHANGE
Target $125
HCWC
Buy
Nektar data 'more robust' than Incyte's, says H.C. Wainwright
The failure of Incyte (INCY) and Merck's (MRK) Phase 3 study negatively impacted trading in Nektar Therapeutics (NKTR) shares on Friday, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note titled "Collateral Damage Not Surprising; Expecting ASCO-18 to Validate the Master T Cell Regulator Hypothesis." At this year's American Society of Clinical Oncology meeting, the analyst expects Nektar and partner Bristol-Myers Squibb (BMY) to unveil data from at least 40 advanced melanoma patients "supported by in-depth biomarker characterization to comprehensively ascertain the rationale of combining NKTR-214 with Opdivo." The rationale for combining NKTR-214 with Opdivo is "more robust" than epacadostat plus Keytruda, the analyst contends. Further, he believes data generated by the NKTR-214 plus Opdivo combination is "unambiguous." Chattopadhyay reiterates a Buy rating on Nektar shares with a $125 price target.

TODAY'S FREE FLY STORIES

GPS

Gap

$28.28

-1.275 (-4.31%)

14:35
04/20/18
04/20
14:35
04/20/18
14:35
Options
Gap put volume heavy and directionally bearish »

Bearish flow noted in Gap…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$84.12

-1.53 (-1.79%)

14:33
04/20/18
04/20
14:33
04/20/18
14:33
Conference/Events
Philip Morris management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

ALXN

Alexion

$105.99

-5.75 (-5.15%)

14:30
04/20/18
04/20
14:30
04/20/18
14:30
Recommendations
Alexion analyst commentary  »

Brazilian generic risk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

14:30
04/20/18
04/20
14:30
04/20/18
14:30
General news
Action Economics Survey results »

Action Economics Survey…

UCBI

United Community Banks

$32.40

0.27 (0.84%)

14:29
04/20/18
04/20
14:29
04/20/18
14:29
Syndicate
Breaking Syndicate news story on United Community Banks »

United Community Banks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

HRTX

Heron Therapeutics

$30.40

0.6 (2.01%)

14:24
04/20/18
04/20
14:24
04/20/18
14:24
Recommendations
Heron Therapeutics analyst commentary  »

Helsinn CINV product no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

TGI

Triumph Group

$26.05

-0.2 (-0.76%)

14:20
04/20/18
04/20
14:20
04/20/18
14:20
Options
Put buying in Triumph Group »

Put buying in Triumph…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
04/20/18
04/20
14:17
04/20/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
04/20/18
04/20
14:16
04/20/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$31.93

0.39 (1.24%)

14:14
04/20/18
04/20
14:14
04/20/18
14:14
Periodicals
Twitter bans ads from Kaspersky Lab, Reuters reports »

Twitter said it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$14.73

0.74 (5.29%)

, WAB

Wabtec

$88.35

4.61 (5.51%)

14:07
04/20/18
04/20
14:07
04/20/18
14:07
Periodicals
GE explores merging transport unit with Wabtec, Reuters says »

GE (GE) is looking into…

GE

General Electric

$14.73

0.74 (5.29%)

WAB

Wabtec

$88.35

4.61 (5.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 24

    Apr

  • 25

    Apr

  • 15

    May

  • 12

    Jun

KMB

Kimberly-Clark

$99.75

-3.59 (-3.47%)

14:05
04/20/18
04/20
14:05
04/20/18
14:05
Technical Analysis
Technical Earnings Preview: Kimberly-Clark near 5-year lows ahead of earnings »

The shares of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 27

    Apr

  • 30

    May

DVMT

Dell Technologies

$73.08

-0.81 (-1.10%)

14:05
04/20/18
04/20
14:05
04/20/18
14:05
Options
Dell Technologies call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

WEN

Wendy's

$17.23

-0.165 (-0.95%)

14:02
04/20/18
04/20
14:02
04/20/18
14:02
Hot Stocks
Wendy's announces 2020 goal of opening over 600 new restaurants globally »

The Wendy's Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 09

    May

  • 30

    May

14:00
04/20/18
04/20
14:00
04/20/18
14:00
General news
Fed Governor Brainard did not break from the gradualist mantra »

Fed Governor Brainard did…

LITE

Lumentum

$59.70

-0.25 (-0.42%)

13:55
04/20/18
04/20
13:55
04/20/18
13:55
Options
Lumentum put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 29

    May

ALXN

Alexion

$104.44

-7.3 (-6.53%)

13:46
04/20/18
04/20
13:46
04/20/18
13:46
Hot Stocks
Alexion drops after Brazil AG says Soliris patent made public »

Shares of Alexion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

AKRX

Akorn

$19.61

0.24 (1.24%)

13:45
04/20/18
04/20
13:45
04/20/18
13:45
Options
Akorn call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:45
04/20/18
04/20
13:45
04/20/18
13:45
General news
FX Action: USD-JPY »

FX Action: USD-JPY topped…

TGT

Target

$70.52

-0.45 (-0.63%)

13:35
04/20/18
04/20
13:35
04/20/18
13:35
Options
Target put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

IWM

iShares Trust Russell 2000 Index Fund

$155.75

-0.65 (-0.42%)

, RUT

Russell 2000 Index

13:35
04/20/18
04/20
13:35
04/20/18
13:35
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

At time of writing, the…

IWM

iShares Trust Russell 2000 Index Fund

$155.75

-0.65 (-0.42%)

RUT

Russell 2000 Index

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$50.43

-0.915 (-1.78%)

, XLRE

Real Estate SPDR

$30.25

-0.25 (-0.82%)

13:33
04/20/18
04/20
13:33
04/20/18
13:33
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

For the last five days,…

XLP

Consumer Staples Sector SPDR

$50.43

-0.915 (-1.78%)

XLRE

Real Estate SPDR

$30.25

-0.25 (-0.82%)

XLK

Technology Select Sector SPDR

$66.26

-0.89 (-1.33%)

XLE

Energy Select Sector SPDR

$73.29

-0.37 (-0.50%)

XLB

S&P Select Materials SPDR

$58.95

-0.41 (-0.69%)

XLF

Financial Select Sector

$27.94

0.065 (0.23%)

SPY

SPDR S&P 500 ETF Trust

$266.75

-2.09 (-0.78%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGMS

Scientific Games

$50.25

0.5 (1.01%)

13:25
04/20/18
04/20
13:25
04/20/18
13:25
Options
Scientific Games call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

ALXN

Alexion

$110.26

-1.48 (-1.32%)

13:21
04/20/18
04/20
13:21
04/20/18
13:21
Periodicals
Brazil can produce generic Soliris after breaking Alexion patent, Bloomberg says »

Brazil's Attorney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

WAB

Wabtec

$82.74

-1 (-1.19%)

, GE

General Electric

$14.46

0.47 (3.36%)

13:18
04/20/18
04/20
13:18
04/20/18
13:18
Hot Stocks
Wabtec rises after report of talks for GE rail business deal »

Shares of Wabtec (WAB)…

WAB

Wabtec

$82.74

-1 (-1.19%)

GE

General Electric

$14.46

0.47 (3.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 24

    Apr

  • 25

    Apr

  • 15

    May

  • 12

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.